Abstract

Small B-cell lymphoid neoplasms (SBCLNs) are a heterogeneous group of diseases characterized by malignant clonal proliferation of mature B-cells. However, the classification of SBCLNs remains a challenge, especially in cases where histopathological analysis is unavailable or those with atypical laboratory findings or equivocal pathologic data. In this study, gene expression profiling of 1039 samples from 27 gene expression omnibus (GEO) datasets was first investigated to select highly and differentially expressed genes among SBCLNs. Samples from 57 SBCLN cases and 102 nonmalignant control samples were used to train a classifier using the NanoString platform. The classifier was built by employing a cascade binary classification method based on the random forest algorithm with 35 refined gene signatures. Cases were successively classified as chronic lymphocytic leukemia/small lymphocytic lymphoma, conventional mantle cell lymphoma, follicular lymphoma, leukemic non-nodal mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia, and other undetermined. The classifier algorithm was then validated using an independent cohort of 197 patients with SBCLNs. Under the distribution of our validation cohort, the overall sensitivity and specificity of proposed algorithm model were >95%, respectively, for all the cases with tumor cell content greater than 0.72. Combined with additional genetic aberrations including IGH-BCL2 translocation, MYD88 L265P mutation, and BRAF V600E mutation, the optimal sensitivity and specificity were respectively found at 0.88 and 0.98. In conclusion, the established algorithm demonstrated to be an effective and valuable ancillary diagnostic approach for the sub-classification and pathologic investigation of SBCLN in daily practice.

Highlights

  • Small B-cell lymphoid neoplasms (SBCLNs) are a group of diseases characterized by malignant clonal proliferation of mature B-cells, mainly including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALTL), lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM), and hairy cell leukemia (HCL)[1]

  • If IGH-BCL2, MYD88 L265P, and BRAF V600E were included as supplemental markers of the model, HCL cases could be identified, and the overall sensitivity and specificity could reach 0.88 (173/ 197) and 0.98 (173/176), respectively (Fig. 3C) (Fig. 5E)

  • In this study, using the NanoString platform, we developed a 35-gene signature-based RNA assay to identify major subtypes of SBCLNs, which was validated by an independent cohort

Read more

Summary

Introduction

Small B-cell lymphoid neoplasms (SBCLNs) are a group of diseases characterized by malignant clonal proliferation of mature B-cells, mainly including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALTL), lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM), and hairy cell leukemia (HCL)[1]. Technologies have been developed to reliably quantify low-throughput gene expression in RNA from either fresh/frozen or formalin-fixed paraffinembedded (FFPE) tissue, allowing the development of clinically relevant RNA assays[9,10,11,12,13,14]. Most of these assays focused on binary classification problems and only address a small proportion of lymphoid neoplasms, limiting their application in clinical practice.

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.